文献速递肝病

基于机器学习模型评估代偿期肝硬化患者门静脉高压严重程度

Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
PubMed 文献 · J Hepatol · 2022-09-22

在代偿期晚期慢性肝病(cACLD)患者中,基于血小板计数、胆红素、国际标准化比值等常规实验室参数构建的3参数和5参数机器学习模型(MLM)可预测临床显著门静脉高压(CSPH,HVPG≥10 mmHg)和严重门静脉高压(HVPG≥16 mmHg)。维也纳队列内部表现稳健,5P-MLM对CSPH和严重PH的AUC分别为0.813和0.887;外部验证数据集表现异质(AUC 0.589-0.887);合并队列训练后CSPH的AUC为0.775(3P)和0.789(5P),严重PH的AUC为0.737(3P)和0.828(5P)。

要点

  • 5P-MLM在维也纳队列对CSPH和严重PH的AUC分别为0.813和0.887,优于肝脏硬度测定(AUC 0.808)。
  • 外部验证数据集表现异质,AUC范围为0.589-0.887。
  • 合并队列训练后3P和5P-MLM对CSPH的AUC分别为0.775和0.789,对严重PH分别为0.737和0.828。

核心结论

  • 内部训练的MLM在维也纳cACLD队列中可靠预测门静脉高压严重程度,但外部验证结果异质。
  • 提出的3P/5P在线工具可可靠识别CSPH或严重PH患者,这些患者存在肝功能失代偿风险。

研究设计与样本

  • 利用维也纳队列(NCT03267615)中cACLD患者的详细实验室检查数据,构建预测CSPH(HVPG≥10 mmHg)和严重PH(HVPG≥16 mmHg)的机器学习模型。
  • 模型在外部数据集中评估,并在合并队列中优化。
  • 共纳入1232例cACLD参与者,维也纳队列163例,验证队列1069例。

主要发现

  • CSPH/严重PH患病率在维也纳队列(n=163)为67.4%/35.0%,在验证队列(n=1069)为70.3%/34.7%。
  • MLM基于3个(3P:血小板计数、胆红素、国际标准化比值)或5个(5P:+胆碱酯酶、+γ-谷氨酰转移酶、+活化部分凝血活酶时间替代国际标准化比值)实验室参数。
  • 5P-MLM对CSPH和严重PH的AUC分别为0.813和0.887,优于肝脏硬度测定(AUC 0.808)。
  • 外部验证数据集表现异质(AUC 0.589-0.887)。
  • 合并队列训练后,3P和5P-MLM对CSPH的AUC分别为0.775和0.789,对严重PH的AUC分别为0.737和0.828。

关键数值与推荐

  • CSPH定义为HVPG≥10 mmHg,严重PH定义为HVPG≥16 mmHg。
  • 3P-MLM参数:血小板计数、胆红素、国际标准化比值。
  • 5P-MLM参数:血小板计数、胆红素、活化部分凝血活酶时间、γ-谷氨酰转移酶、胆碱酯酶。

临床怎么用

  • 基于3个或5个广泛可用的实验室参数的在线计算器可供临床医生预测cACLD患者存在临床显著或严重门静脉高压的可能性。

局限性

  • MLM在外部验证数据集中的性能异质(AUC 0.589-0.887)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: In individuals with compensated advanced chronic liver disease (cACLD), the severity of portal hypertension (PH) determines the risk of decompensation. Invasive measurement of the hepatic venous pressure gradient (HVPG) is the diagnostic gold standard for PH. We evaluated the utility of machine learning models (MLMs) based on standard laboratory parameters to predict the severity of PH in individuals with cACLD. METHODS: A detailed laboratory workup of individuals with cACLD recruited from the Vienna cohort (NCT03267615) was utilised to predict clinically significant portal hypertension (CSPH, i.e., HVPG ≥10 mmHg) and severe PH (i.e., HVPG ≥16 mmHg). The MLMs were then evaluated in individual external datasets and optimised in the merged cohort. RESULTS: Among 1,232 participants with cACLD, the prevalence of CSPH/severe PH was similar in the Vienna (n = 163, 67.4%/35.0%) and validation (n = 1,069, 70.3%/34.7%) cohorts. The MLMs were based on 3 (3P: platelet count, bilirubin, international normalised ratio) or 5 (5P: +cholinesterase, +gamma-glutamyl transferase, +activated partial thromboplastin time replacing international normalised ratio) laboratory parameters. The MLMs performed robustly in the Vienna cohort. 5P-MLM had the best AUCs for CSPH (0.813) and severe PH (0.887) and compared favourably to liver stiffness measurement (AUC: 0.808). Their performance in external validation datasets was heterogeneous (AUCs: 0.589-0.887). Training on the merged cohort optimised model performance for CSPH (AUCs for 3P and 5P: 0.775 and 0.789, respectively) and severe PH (0.737 and 0.828, respectively). CONCLUSIONS: Internally trained MLMs reliably predicted PH severity in the Vienna cACLD cohort but exhibited heterogeneous results on external validation. The proposed 3P/5P online tool can reliably identify individuals with CSPH or severe PH, who are thus at risk of hepatic decompensation. IMPACT AND IMPLICATIONS: We used machine learning models based on widely available laboratory parameters to develop a non-invasive model to predict the severity of portal hypertension in individuals with compensated cirrhosis, who currently require invasive measurement of hepatic venous pressure gradient. We validated our findings in a large multicentre cohort of individuals with advanced chronic liver disease (cACLD) of any cause. Finally, we provide a readily available online calculator, based on 3 (platelet count, bilirubin, international normalised ratio) or 5 (platelet count, bilirubin, activated partial thromboplastin time, gamma-glutamyltransferase, choline-esterase) widely available laboratory parameters, that clinicians can use to predict the likelihood of their patients with cACLD having clinically significant or severe portal hypertension.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Reiniš J, Petrenko O, Simbrunner B, et al. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis. J Hepatol. 2022. PMID: 36152767. doi:10.1016/j.jhep.2022.09.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。